

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/809,346	03/26/2004	Yoshinobu Yamazaki	Q80493	-7551		
23373 7590 01/28/2008 SUGHRUE MION, PLLC			EXAMINER			
	2100 PENNSYLVANIA AVENUE, N.W.			HENLEY III, RAYMOND J		
SUITE 800 WASHINGTO	N DC 20037		ART UNIT	PAPER NUMBER		
WAGIIINGTO	11, DC 20037		1614	•		
			MAIL DATE	DELIVERY MODE		
			01/28/2008	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/809,346	YAMAZAKI ET AL.		
Examiner	Art Unit		
Raymond J. Henley III	1614		

	Raymond J. Henley III	1614				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 17 December 2007 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.				
 The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No. (3) a Request for Continued Examination (RCE) in completion following time periods: 	wing replies: (1) an amendment, a ptice of Appeal (with appeal fee) in	ffidavit, or other evide compliance with 37 (ence, which CFR 41.31; or			
a) The period for reply expires 5 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO						
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f) Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened sta above, if checked. Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	which the petition under 37 CFR 1.136(a nd the corresponding amount of the fee. tutory period for reply originally set in the	The appropriate extension final Office action; or (2)	n fee under 37 as set forth in (b)			
 The Notice of Appeal was filed on A brief in composition of filing the Notice of Appeal (37 CFR 41.37(a)), or any expine a Notice of Appeal has been filed, any reply must be AMENIMATICE. 	ktension thereof (37 CFR 41.37(e))), to avoid dismissal o	of the appeal.			
AMENDMENTS	h	المحسفية مطاعمة الثناء				
 The proposed amendment(s) filed after a final rejection, They raise new issues that would require further contains the proposed in t	nsideration and/or search (see NO		Decause			
(c) They are not deemed to place the application in bet appeal; and/or	•	educing or simplifying	the issues for			
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally re	jected claims.				
4. The amendments are not in compliance with 37 CFR 1.1 5. Applicant's reply has overcome the following rejection(s)		ompliant Amendment	(PTOL-324).			
6. Newly proposed or amended claim(s) would be a	llowable if submitted in a separate					
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows: Claim(s) allowed:	□ will not be entered, or b)	ill be entered and an	explanation of			
Claim(s) objected to: Claim(s) rejected:						
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and and was not earlier presented. See 37 CFR 1.116(e). 						
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessar	vercome <u>all</u> rejections under appe y and was not earlier presented. S	al and/or appellant fa See 37 CFR 41.33(d)(ils to provide a 1).			
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	entry is below or attac	hed.			
 The request for reconsideration has been considered bu <u>See Continuation Sheet.</u> 	t does NOT place the application i	n condition for allowa	nce because:			
12. ☐ Note the attached Information Disclosure Statement(s).13. ☐ Other:	(PTO/SB/08) Paper No(s).	D M	/8			
		Raymond J Henley Primary Examinet Art Unit: 1614	The state of the s			

PRIMARY EXAMIN

Continuation of 11. does NOT place the application in condition for allowance because of reasons of record and those which follow.

The Examiner will agree that "urgency" is different thant "urinary incontinence" and "frequency" as stressed by Applicants at page 10 of their remarks, third full paragraph, "Thus, the definition means that...'urgency' is different than 'urinary incontinence' and 'frequency' and is seem [sic] independently of whether or not urinary incontinence and/or pollakiuria coexist or not". This, however, does not diminish the propriety of the present rejection because the rejection does not rest or otherwise depend on whether "urgency" means the same as "urinary incontinence" or "frequency".

The invention as is now claimed is a "method for treating urinary incontinence associated with overactive bladder" which involves the administration of certain, claimed defined compounds.

It remains that Tanaka et al. expressly teach a method for the treatment of urinary incontinence with the presently claimed

The difference, then, between the reference's teaching and the claimed subject matter is that urinary incontinence "associated with overactive bladder" is not disclosed by Tanaka et al..

However, Tanaka et al. does not limit the treatment to any particular type of urinary incontinence. Thus, thus one of ordinary skill in the art would have recognized that the teachings of Tanaka et al. apply to the treatment of urinary incontinence having a cause known in the art, including the urinary incontinence which was known to be associated with overactive bladder. Such an association was referenced not only in the art relied upon by the Examiner, (see Short et al. or Guittard et al.), but also newly acknowledged by Applicants in their statement. "In detail, before filing the present application, OAB was clearly defined as a syndrome of urgency, WITH or without INCONTINENCE, usually with frequency and nocturia", (emphasis added; remarks at page 9, first paragraph).

The rejection of claims 1-19 is thus deemed to remain proper.

2